Company Overview - DIH Holding US, Inc. is a global provider of advanced robotic devices for rehabilitation, focusing on patients with walking impairments, reduced balance, and impaired arm and hand functions [1][4] - The company aims to improve the daily lives of individuals with disabilities through intensive rehabilitation solutions [4] Leadership Appointment - Scott R. Burell has been appointed to the Board of Directors, bringing over two decades of experience in healthcare finance and a strong background in life sciences [2][3] - Burell's previous roles include Chief Financial Officer at AIVITA Biomedical and CombiMatrix Corporation, where he successfully led complex transactions and M&A activities [2] Strategic Vision - CEO Jason Chen expressed confidence in Burell's financial expertise and experience in the life sciences sector, which will enhance the company's growth strategy [3] - Burell highlighted the significant opportunities in the growing rehabilitation robotics market and his commitment to supporting the company's mission [3] Board Composition - The Board of Directors now consists of six members, including four independent members, reinforcing the company's commitment to strong governance practices [3]

Company Overview - DIH Holding US, Inc. aims to "Deliver Inspiration & Health" by providing devices and solutions for intensive rehabilitation, targeting individuals with disabilities and functional impairments [4] - The company is a global provider of advanced robotic devices for physical rehabilitation, focusing on interactive visual stimulation to aid clinical research and rehabilitation for patients with walking impairments and reduced balance [4] - DIH has emerged through the mergers of leading niche technology providers, positioning itself as a transformative solutions provider in a fragmented industry [4] Compliance and Reporting - On July 29, 2025, DIH received a notice from Nasdaq indicating non-compliance with Listing Rule 5250(c)(1) due to the failure to file its Annual Report on Form 10-K for the period ended March 31, 2025 [1] - The company has 60 calendar days from the notice date to file the Annual Report, with the option to submit a compliance plan if unable to meet the deadline [2] - If the compliance plan is accepted, DIH may be granted up to 180 additional days to regain compliance [2] - The company is actively working with auditors and advisors to file the Annual Report as soon as possible, and the notice does not have an immediate impact on the listing or trading of its securities [3]

Core Insights - DIH Holding US, Inc. has appointed Dennis Streppa to its Board of Directors and as Chair of the Audit Committee, enhancing its governance structure [1][3] - Dennis Streppa brings extensive experience in public and private healthcare, having driven M&A value and managed significant business operations [2][3] - The Board now consists of five members, including three independent members, reinforcing the company's commitment to strong governance [3] Company Overview - DIH is a global provider of advanced robotic devices aimed at rehabilitation, focusing on patients with walking impairments, reduced balance, and impaired arm and hand functions [1][4] - The company aims to "Deliver Inspiration & Health" by improving the lives of individuals with disabilities through innovative rehabilitation solutions [4] - DIH has emerged as a transformative provider in a fragmented industry, consolidating various niche technology providers to enhance rehabilitation services [4]

Company Overview - DIH Holding US, Inc. is a global provider of advanced robotic devices for rehabilitation, focusing on patients with walking impairments, reduced balance, and impaired arm and hand functions [1][5] - The company aims to improve the daily lives of millions with disabilities through intensive rehabilitation solutions [5] Appointment of Professor Nick Ward - Professor Nick Ward, M.D. has been appointed to the DIH Scientific Advisory Board, bringing expertise in upper limb neurorehabilitation [1][4] - His role will involve providing insights into clinical practices and supporting the development of new approaches for motor recovery after stroke [4] Scientific Advisory Board (SAB) Composition - The DIH SAB consists of leading scientists and clinicians with diverse expertise relevant to DIH's rehabilitation solutions [3] - With the addition of Professor Ward, the SAB now includes nine distinguished members, enhancing the company's commitment to evidence-based innovation [4]

Core Insights - DIH Holding US, Inc. has appointed Rehazentrum Valens as a Center of Excellence, emphasizing their commitment to enhancing rehabilitation through innovative technologies [1][5] - The partnership aims to improve patient outcomes and support recovery journeys by integrating advanced rehabilitation technologies [1][2] Company Overview - DIH is a global provider of advanced robotic devices for rehabilitation, focusing on patients with walking impairments and other functional disabilities [1][6] - The company aims to deliver inspiration and health by blending robotic and virtual reality technologies with clinical insights [6] Rehazentrum Valens Profile - Established in 1970, Rehazentrum Valens is a leading rehabilitation center in Switzerland, specializing in neurological, musculoskeletal, and internal medicine rehabilitation [3][7] - The center is recognized for its interdisciplinary collaboration and patient-centered care, aiming to restore independence and quality of life for patients [3][8] Rehabilitation Technologies - Rehazentrum Valens utilizes DIH's Total Solution, including devices like ErigoPro, LokomatPro, Andago, and C-Mill VR+, to enhance rehabilitation programs [4] - The Armeo product family is also employed for advanced arm and hand therapy, catering to a wide range of patient needs [4] Strategic Importance - The recognition of Rehazentrum Valens as a DIH Center of Excellence highlights its leadership in evidence-based rehabilitation and commitment to integrating advanced technologies into patient care [5] - This partnership is expected to shape the future of rehabilitation by combining clinical excellence with innovative solutions [5]

Revenue Performance - Revenue for Q3 2024 decreased by $3.9 million, or 20.6%, to $15.1 million from $19.0 million in Q3 2023[5] - Device revenue declined by 26% to $11.7 million, while service revenue grew by 4% to $3.1 million compared to the prior year[10] - Total revenue in the EMEA region decreased by 29% to $8.7 million, while revenue in the Americas decreased by 7% to $3.5 million[10] Profitability and Expenses - Gross profit for Q3 2024 was $7.2 million, a decrease of 30.4% year-over-year, primarily due to lower sales in the EMEA region[7] - Selling, general and administrative expenses increased by $2.8 million, or 50.6%, to $8.2 million, driven by higher employee compensation and overhead costs[8] - Research and development costs rose by $0.1 million, or 7.7%, to $1.8 million, mainly due to increased amortization expenses[9] - Net income for the three months ended December 31, 2025, was a loss of $3,728 thousand, compared to a profit of $2,969 thousand for the same period in 2024, representing a significant decline[23] - Comprehensive loss for the nine months ended December 31, 2024, was $6,496 thousand, compared to a loss of $2,616 thousand for the same period in 2023, indicating a worsening financial position[23] Cash Flow and Liquidity - Cash flows from operating activities for the nine months ended December 31, 2024, resulted in a net cash outflow of $848 thousand, compared to an inflow of $3,177 thousand for the same period in 2023[26] - Cash, cash equivalents, and restricted cash at the end of the period were $1,120 thousand, down from $1,679 thousand at the end of the previous year, indicating liquidity challenges[26] - Cash and cash equivalents totaled $1.1 million as of December 31, 2024[11] Equity and Financial Position - Total equity decreased to $(37,882) thousand as of December 31, 2024, from $(34,395) thousand as of September 30, 2024, indicating a decline in shareholder value[24] - The net transactions with the parent company resulted in an increase of $450 thousand in equity during the three months ended December 31, 2024[24] Asset Management - The company incurred depreciation and amortization expenses of $611 thousand for the nine months ended December 31, 2024, compared to $230 thousand for the same period in 2023, highlighting increased asset utilization[26] - The allowance for inventory obsolescence was $(67) thousand for the nine months ended December 31, 2024, a significant change from $705 thousand in the same period of 2023, suggesting improved inventory management[26] Future Outlook - The company reiterated its revenue guidance for fiscal year 2025, expecting a range between $60 million and $67 million[12] Collaborations - The company announced collaborations with Nobis Rehabilitation Partners and Zahrawi Group to expand its distribution network[10] Foreign Exchange Impact - The company reported a foreign exchange loss of $(241) thousand for the nine months ended December 31, 2024, compared to a gain of $181 thousand for the same period in 2023, reflecting adverse currency movements[26]

Core Insights - DIH Holding US, Inc. reported financial results for the third fiscal quarter ended December 31, 2024, showing a revenue decline of 20.6% year-over-year, primarily due to challenges in the EMEA region caused by import restrictions related to the Russia-Ukraine conflict [3][4][8] - The company reiterated its full-year revenue guidance for fiscal year 2025, maintaining a target range of $60 million to $67 million, despite current challenges [3][11] Financial Performance - Revenue for the third quarter was $15.1 million, down from $19.0 million in the same quarter of the previous year, with device sales decreasing by 25.6% to $11.7 million [4][8] - Gross profit decreased by 30.4% to $7.2 million, driven by lower sales volumes, while cost of sales decreased by 8.7% to $7.9 million [6][21] - Selling, general, and administrative expenses increased by 50.6% to $8.2 million, attributed to higher employee compensation and overhead costs [7][21] Regional Sales Performance - Revenue in the EMEA region decreased by 29% to $8.7 million, while revenue in the Americas decreased by 7% to $3.5 million [4][8] - The decline in EMEA sales was significantly impacted by wartime import restrictions affecting one of the company's largest sales partners in Eastern Europe [4][8] Partnerships and Future Outlook - The company has formed new partnerships with Nobis Rehabilitation Partners and Zahrawi Group, which are expected to enhance its distribution network and device integration capabilities [8] - Following a recent public offering that raised approximately $4.6 million, the company is positioned to meet order demand and support future growth initiatives [3][12] Cash Position - As of December 31, 2024, cash and cash equivalents totaled $1.1 million, a decrease from $3.2 million at the beginning of the period [10][28]

Core Viewpoint - DIH Holding US, Inc. has expanded its strategic partnership with Zahrawi Group to include Saudi Arabia, enhancing the distribution of advanced robotic rehabilitation devices across four countries in the Gulf region [1][3][4] Group 1: Company Overview - DIH is a global provider of advanced robotic devices for rehabilitation, focusing on patients with walking impairments, balance issues, and impaired arm and hand functions [1][5] - Zahrawi Group, established in 1989, is a leading medical devices and life science provider in the Gulf Cooperation Council, specializing in various healthcare solutions [2][6] Group 2: Partnership Expansion - The partnership aims to improve the accessibility of DIH's rehabilitation solutions, leveraging Zahrawi Group's established presence in the healthcare sector [3][4] - The collaboration will focus on delivering innovative technologies to enhance patient outcomes and support healthcare professionals [3][4] Group 3: Strategic Goals - The expanded partnership reflects both companies' commitment to innovation and high-quality rehabilitation solutions, aiming to make a significant impact on rehabilitation services in the Middle East [4]

Core Viewpoint - DIH Holding US, Inc. has successfully closed a public offering of 5,937,100 units at a price of $0.7832 per unit, aiming to enhance its capital for rehabilitation technology development [1][2]. Group 1: Offering Details - The offering consisted of units, each comprising one share of Class A common stock and one Class A warrant, with an exercise price of $0.7832 per share [1]. - The gross proceeds from the offering were approximately $4.6 million, which will be allocated for capital expenditures, working capital, and general corporate purposes [2]. Group 2: Company Overview - DIH is a global provider of advanced robotic devices for rehabilitation, focusing on patients with walking impairments, balance issues, and impaired arm and hand functions [5]. - The company aims to improve the lives of individuals with disabilities through innovative rehabilitation solutions, consolidating a fragmented industry [5].

Company Overview - DIH Holding US, Inc. is a global provider of advanced robotic devices for rehabilitation, focusing on patients with walking impairments, reduced balance, and impaired arm and hand functions [1][5] - The company aims to improve the daily lives of individuals with disabilities through innovative rehabilitation solutions [5] Public Offering Details - DIH announced a public offering of 5,937,100 units at a price of $0.7832 per unit, with each unit consisting of one share of Class A common stock and one Class A warrant [1] - The gross proceeds from the offering are expected to be approximately $4.6 million, which will be used for capital expenditures, working capital, and general corporate purposes [2] Securities Registration - The offering is conducted under a registration statement on Form S-1, which was declared effective by the SEC on January 31, 2025 [3] - A preliminary prospectus has been filed with the SEC, and electronic copies of the final prospectus will be available on the SEC's website [3] Placement Agent - Maxim Group LLC is acting as the sole placement agent for the offering [2]